Oncolytics Biotech Q2 EPS $(0.09), Inline; Cash, Cash Equivalents Of $24.4M
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech reported Q2 losses of $(0.12) per share, missing the analyst consensus estimate of $(0.09) by 33.33%. This is a 71.43% decrease from the same period last year. The company reported $24.4 million in cash, cash equivalents, and marketable securities as of June 30, 2023, and closed a $15 million public offering on August 8, 2023.
August 14, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Oncolytics Biotech's Q2 earnings missed estimates, which could negatively impact the stock. However, the company has a strong cash position and recently closed a $15 million public offering.
The company's earnings miss could lead to a short-term decrease in the stock price. However, the company's strong cash position and recent public offering could offset some of this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100